Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Mingjia LiDaniel SpakowiczSongzhu ZhaoSandip H PatelAndrew JohnsMadison GroganAbdul MiahMarium HusainKai HeErin M BertinoPeter G ShieldsLai WeiDavid P CarboneGregory A OttersonCarolyn J PresleyDwight H OwenPublished in: Cancer immunology, immunotherapy : CII (2020)
Patients treated with ICS at time of ICI initiation had an increased risk of developing CIP. We further identified older adults with age ≥ 65 years and lung cancers as independent risk factors for CIP.